Supplemental Financial Information (Tables)

9 Months Ended

Sep. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The following table presents the components of inventories (in thousands):


	September 30, 2026		December 31, 2025
Raw materials	$	65,110	$	75,800
Work-in-process	32,615		12,875
Finished goods	80,156		76,026
	$	177,881	$	164,701

Schedule of Accrued Liabilities and Other

The following table presents the components of accrued liabilities and other (in thousands):


	September 30, 2026		December 31, 2025
Legal and professional costs	$	17,467	$	18,396
Italian MedTech payback measure	14,526		12,839
Product liability litigation provision (1)	27,824		12,552
Contract liabilities	13,643		11,510
Operating lease liabilities	9,187		8,788
Royalty accrual	5,284		4,758
Provisions for agents, returns, and other	3,907		5,322
Tariff refund payable	1,943		—
Research and development costs	1,303		1,234
Interest payable	650		4,638
Current derivative liabilities (2)	148		99
Other accrued expenses	33,052		26,989
	$	128,934	$	107,125

(1)Refer to “Note 6. Commitments and Contingencies.”

(2)Refer to “Note 3. Derivatives and Risk Management.”

Schedule of Foreign Exchange and Other Income/(Expense)

The following table presents the items included in foreign exchange and other income/(expense) on the condensed consolidated statements of income (loss) (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Fair value adjustment - 2029 Embedded Derivative (1)	$	28,152	$	(16,422)	$	(40,848)	$	(12,696)
Fair value adjustment - 2029 Capped Calls (1)	(4,700)		6,353		16,042		4,276
Gain on sale of investment (2)	—		—		13,648		—
Interest income	3,896		3,899		11,279		14,525
FX fluctuations	(1,039)		(613)		(2,407)		(2,463)
Impairment of investment	—		(1,112)		(1,132)		(1,112)
Investment revaluation - Ceribell, Inc. (3)	—		—		—		(3,622)
Fair value adjustment - 2025 Embedded Derivative (1)	—		(322)		—		1,230
Fair value adjustment - 2025 Capped Calls (1)	—		324		—		(997)
Other	(8)		400		195		527
	$	26,301	$	(7,493)	$	(3,223)	$	(332)

(1)Refer to “Note 4. Fair Value Measurements.”

(2)In June 2026, one of LivaNova’s equity investments was acquired by a third party, resulting in consideration of $17.1 million and the recognition of a gain on sale of $13.6 million for the nine months ended September 30, 2026.

(3)During the nine months ended September 30, 2025, LivaNova liquidated its investment in Ceribell, Inc., consisting of 391,952 common shares, in a series of transactions with an average sales price of $16.69 per common share, resulting in net proceeds of $6.5 million from an initial investment in 2018 of $3.0 million.

Schedule of Supplemental Disclosures Cash Flow

The following table presents supplemental information to the condensed consolidated statements of cash flows (in thousands):


	Nine Months Ended September 30,
	2026		2025
Supplemental noncash investing and financing transactions:
Receivable from sale of investment	$	7,991	$	—
Assets obtained in exchange for operating lease obligations	10,167		9,898
Capital expenditures included in accounts payable	7,597		3,758